Latest Industry Insights

The World Health Organization recognizes that, as of June 22, there are over 140 vaccines against COVID-19 in various stages of development. 13 of those candidates are now in human clinical trials. In this insights piece, we explore what those candidates are, and who is developing them.

A number of biopharmaceutical industry leaders met in a virtual press conference today to outline progress in COVID-19 vaccine development. Here's what they had to say.

In facilitating the move to continuous processing in biotherapeutic production, bioprocessing specialists are being driven to develop innovative analytical testing methods for key measurements of output and quality, such as antibody titer.

In a study published in Cell Reports, members of the Washburn Lab described their three-pronged approach to analyzing protein complexes – affinity tag protein purification, chemical crosslinking with high-resolution mass spectrometry and computational molecular modeling with protein docking. We interviewed Washburn to find out more.

Jagannath Swaminathan is the co-founder of Erisyon and a researcher at the Marcotte Lab at the University of Texas Austin. In this interview, we discuss the concept of next-generation protein sequencing, clinical proteomics and the critical role of protein sequencing in the fight against COVID-19.

Proteins are central to many disciplines within the life sciences, not least protein-based pharmaceuticals. Changes in protein conformation, structure or interactions could have significant impact on efficacy and safety. Therefore, being able to understand what forms of a protein are present in their natural conditions, even if present only at low levels, is important for analysts.

Technology Networks recently had the pleasure of speaking with Keith Murphy, CEO and founder of Viscient Biosciences to learn about the company's expertise in 3D disease models and multi-omics drug discovery approaches, and how they are using these techniques to test drugs against SARS-CoV-2 using bioprinted lung tissue.

Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn about the biotech company's proprietary platform, the challenges encountered in developing cell therapies and to gain Mogrify's insights on the future of this exciting research space.

Technology Networks recently spoke with Gary Kruppa, PhD, Vice President of Proteomics, Bruker Daltonics Inc., to learn more about the advancing research area immunopeptidomics, and to discuss the current status of single cell proteomics.

Technology Networks spoke with Stephen Williams, Chief Medical Officer of SomaLogic, to learn about how proteomics can contribute to the fight against COVID-19 and the availability of the SomaScan Assay at this critical time.